For the Inventor, By the Inventor

Enter assignee name

Costa Mesa, CA, United States of America

Icn Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 46

Trademarks = 12

Forward Citations = 1,534

Loading Chart...

Loading Chart...

42 inventors (with patents filed for the assignee):

Roland K Robins (14 out of 34 patents)

Robert C Tam (9 out of 21 patents)

Kandasamy Ramasamy (8 out of 11 patents)

4. Guangyi Wang (7 out of 55 patents)

5. Devron R Averett (7 out of 24 patents)

6. Joseph T Witkowski (6 out of 14 patents)

7. Zbigniew Pietrzkowski (4 out of 29 patents)

8. Wilfried E Seifert (3 out of 4 patents)

9. Dariusz Cieslak (3 out of 3 patents)

10. Dennis A Shuman (3 out of 3 patents)

11. Darrell E O'Brien (3 out of 3 patents)

12. Ganapathi R Revankar (3 out of 10 patents)

13. Gordana Olbina (2 out of 2 patents)

14. Joseph Sandor (2 out of 10 patents)

15. Roland K Robins, Deceased (2 out of 3 patents)

Core Competencies:

Monocyclic L-Nucleosides

C-Nucleosides

Oligonucleotide Analogs

Purine Derivatives

Th1/Th2 Cytokine Modulation

Antisense Oligonucleotides

Xanthine Oxidase Inhibitors

Carbohydrate Conjugates

Nitric Oxide Adducts

Triazole Nucleosides

Tumor Growth Inhibition

Vitamin B-12 Delivery

46 patents: Sort by Forward Citations

1. 6642206 - Monocyclic L-nucleosides, analogs and uses thereof (2003-11-04),

2. 6613896 - Method of producing tiazofurin and other C-nucleosides (2003-09-02),

3. 6573248 - Monocyclic L-nucleosides, analogs and uses thereof (2003-06-03),

4. 6552183 - Moncyclic L-nucleosides analogs (2003-04-22),

5. 6509320 - Purine L-nucleosides, analogs and uses thereof (2003-01-21),

6. 6479463 - Purine L-nucleosides, analogs and uses thereof (2002-11-12),

7. 6403566 - Nucleosides having bicyclic sugar moiety (2002-06-11),

8. 6211201 - Multivalent salts of pyridostigmine and related compounds (2001-04-03),

9. 6191266 - Sugar modified nucleosides (2001-02-20),

10. 6150337 - Specific modulation of Th1/Th2 cytokine expression by Ribavirin in (2000-11-21),

11. 6130326 - Monocyclic L-Nucleosides, analogs and uses thereof (2000-10-10),

12. 6110453 - Polymer-bound nitric oxide/nucleophile adduct compositions, (2000-08-29),

13. 6083482 - Conformationally locked nucleosides and oligonucleotides (2000-07-04),

14. 6063772 - Specific modulation of Th1/Th2 cytokine expression by ribavirin in (2000-05-16),

15. 6017898 - Inhibition of tumor growth by antisense oligonucleotides for IL-8 and (2000-01-25),

Company Overview

Icn Pharmaceuticals, Inc., based in Costa Mesa, CA, specializes in the development of innovative therapeutic solutions, focusing on advanced nucleoside technologies. The company is engaged in research and manufacturing of monocyclic and bicyclic nucleosides, as well as antisense oligonucleotides, which are pivotal in the treatment of various diseases. Their expertise extends to cytokine modulation and the creation of carbohydrate conjugates, positioning them at the forefront of biopharmaceutical advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

46 Patents

#9 in Costa Mesa, CA

#1,798 in California

#7,614 in US

#15,133 in the World

Costa Mesa, CA, United States of America

Icn Pharmaceuticals, Inc.

Forward Citations = 1,534

42 inventors:

Roland K Robins (14 out of 34 patents)

Robert C Tam (9 out of 21 patents)

Kandasamy Ramasamy (8 out of 11 patents)

4. Guangyi Wang (7 out of 55 patents)

5. Devron R Averett (7 out of 24 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Icn Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/icn-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…